Featured Research

from universities, journals, and other organizations

Estimate of amount of radiotherapy dose wasted in compensating for tumour growth between treatments

Date:
September 30, 2013
Source:
The European CanCer Organisation (ECCO)
Summary:
For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer.

For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer.

In research to be presented to the 2013 European Cancer Congress (ECC2013), Professor John Yarnold will say that, until now, there has been contradictory evidence as to whether gaps between radiotherapy treatments, for instance overnight or at weekends, makes any difference to the overall effectiveness of radiotherapy on breast cancer, and, if it does make a difference, why that could be.

"Traditionally, breast cancer has not been regarded as a fast growing cancer, unlike some other cancer types, but our research now suggests that a significant part of the daily radiotherapy curative dose is 'used up' in compensating for tumour growth overnight and over weekends. We have estimated that the amount of radiotherapy dose that is used up in this way corresponds to approximately 0.60 Gray (Gy) per day," says Prof Yarnold, who is Professor of Clinical Oncology at The Institute of Cancer Research, London, and Honorary Consultant at the Royal Marsden NHS Foundation Trust (London, UK).

"This is the first numerical estimate to suggest that the duration of a course of radiotherapy has an effect on local cancer cure for patients with early breast cancer. The results of our analysis are hypothesis-generating; they offer an explanation as to why prolonged radiotherapy schedules may allow cancer cells to fight back, and suggest that breast cancer cell growth rates after surgery are higher than historically assumed. If confirmed, it means that current trends to deliver shorter radiotherapy schedules are likely to bear fruit in the future. However, I should emphasise that current schedules delivered over five weeks or more remain highly effective, and patients should follow recommendations from their specialists."

Radiotherapy is normally given as a series of treatments over a number of weeks in order to destroy any remaining cancer cells in the breast, chest wall or underarm area after surgery, and to reduce the risk of the cancer recurring in the same breast, while, at the same time, minimising harm to the healthy tissues.

Prof Yarnold and Ms Jo Haviland, a senior statistician at The Institute of Cancer Research (ICR) Clinical Trials and Statistics Unit (CTSU) based their research on the Standardisation of Breast Radiotherapy (START) trials (START Pilot, START A and START B), which have been evaluating the effects of giving shorter radiotherapy schedules after surgery for early breast cancer patients in the UK since 1986.

The researchers used data from 5,861 UK patients who were enrolled between 1986 and 2002 into the three START randomised clinical trials that compared different schedules for delivering radiotherapy. The START Pilot and START A trials compared the international standard of giving a total of 50 Gy in 25 daily doses of 2.0 Gy over five weeks versus two other schedules of slightly higher daily doses of 3.0-3.3 Gy over the same time period. The START B trial compared the international standard (50 Gy in 25 daily doses of 2.0 Gy over five weeks) with a shorter schedule giving a total of 40 Gy in 15 daily doses of 2.67 Gy over three weeks. After a follow-up period of ten years, the three-week schedule was shown to be as good as the five-week schedule at preventing the cancer from recurring in the same breast and has since been adopted as the standard in the UK. In terms of safety, the three-week schedule was gentler on the normal tissues, with fewer late side-effects.

Using the data from these trials, the researchers then estimated the effect of overall radiotherapy treatment time on the risk of the cancer recurring, comparing the three-week schedule with the five-week schedules. They used a statistical model that took into account the total dose, the size of the daily dose, the length of time over which the radiotherapy was given, and factors known to be associated with the risk of the cancer recurring in the same breast. They found that approximately 0.60 Gy of the daily radiotherapy dose was being wasted during the five-week treatment schedules to compensate for cancer cells growing.

"This suggests that a shorter one-week radiotherapy schedule, replacing the five to seven-week schedules that were more usual in the past, may be more effective against breast cancer recurrence and reduce the chances of side-effects on the surrounding normal tissues. In addition, shorter treatment schedules would be more convenient for patients, with benefits including fewer trips to the hospital, and also highly cost-effective for health services," says Prof Yarnold.

Future work will investigate whether reducing the overall treatment time further is as safe and as effective as the current three-week schedule which has been standard practice in the UK since 2009, following publication of the five-year results from the START A and START B trials.

"The UK FAST Forward phase III trial is an example of this research, comparing the current UK standard three-week schedule with two radiotherapy dose levels of a one-week schedule in women with early breast cancer. This trial is well on the way to recruiting 4000 women," he will conclude.

President of ECCO, Professor Cornelis van de Velde, commented: "This is important research that suggests that the overall treatment time with radiotherapy could make a difference to outcomes for women with early breast cancer. If further investigations confirm that a shorter radiotherapy schedule is as effective as the current standard of care, it will be another step towards making treatments easier and more bearable for patients, and possibly cheaper for healthcare services."


Story Source:

The above story is based on materials provided by The European CanCer Organisation (ECCO). Note: Materials may be edited for content and length.


Cite This Page:

The European CanCer Organisation (ECCO). "Estimate of amount of radiotherapy dose wasted in compensating for tumour growth between treatments." ScienceDaily. ScienceDaily, 30 September 2013. <www.sciencedaily.com/releases/2013/09/130930093514.htm>.
The European CanCer Organisation (ECCO). (2013, September 30). Estimate of amount of radiotherapy dose wasted in compensating for tumour growth between treatments. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2013/09/130930093514.htm
The European CanCer Organisation (ECCO). "Estimate of amount of radiotherapy dose wasted in compensating for tumour growth between treatments." ScienceDaily. www.sciencedaily.com/releases/2013/09/130930093514.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins